2007
DOI: 10.1111/j.1600-0536.2006.00950.x
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Parthenium dermatitis with methotrexate

Abstract: Patients with parthenium dermatitis are often unresponsive to topical steroids, and immunosuppressive agents may be necessary to reduce their need for systemic corticosteroids. We evaluated the efficacy of methotrexate in parthenium dermatitis. Sixteen patients unresponsive to topical treatment were included after baseline investigations, and treated with oral methotrexate (15 mg/week). Clinical response was monitored using a dermatitis area and severity index (DASI). Seven patients completed >or=6 months' fol… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
23
0
2

Year Published

2011
2011
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(26 citation statements)
references
References 6 publications
1
23
0
2
Order By: Relevance
“…The beneficial effect of methotrexate in parthenium dermatitis studied previously showed 50% improvement in dermatitis within 1 month of initiation of therapy with a sustained decrease in the dermatitis score with continuation of methotrexate for 6 months. [6] Our study, also shows >75% reduction in CSS within 5.6 weeks. In conclusion, though both azathioprine and methotrexate are effective and safe steroid-sparing agents in the treatment of parthenium-induced ABCD, methotrexate helps in achieving an earlier control of the dermatitis and is a cheaper alternative to azathioprine.…”
supporting
confidence: 60%
“…The beneficial effect of methotrexate in parthenium dermatitis studied previously showed 50% improvement in dermatitis within 1 month of initiation of therapy with a sustained decrease in the dermatitis score with continuation of methotrexate for 6 months. [6] Our study, also shows >75% reduction in CSS within 5.6 weeks. In conclusion, though both azathioprine and methotrexate are effective and safe steroid-sparing agents in the treatment of parthenium-induced ABCD, methotrexate helps in achieving an earlier control of the dermatitis and is a cheaper alternative to azathioprine.…”
supporting
confidence: 60%
“…A trial with dexamethasone-cyclophosphamide pulse therapy was unsuccessful 15. Methotrexate has also been reported to be effective at a dose of 15 mg/week along with topical corticosteroids and sunscreens 16. There are no reports on CDP treated with methotrexate and intralesional triamcinolone acetonide.…”
Section: Discussionmentioning
confidence: 99%
“…Bu ilk adımdan sonra topikal (steroidler, topikal kalsinörin inhibitörler, nemlendiriciler) ve sistemik (steroidler, metotreksat, azothioprin) gibi birçok ajan kullanılabilir (42)(43)(44)(45)(46). Ancak tedavinin kısa ve uzun dönemde başarısının esas anahtarı kontakt dermatit etkenini bulup ortadan kaldırmaktır, nitekim ajanla teması kesilemeyen olgularda şikayetler işe dönünce tekrarlamaktadır (42).…”
Section: Tedavi Ve Korunmaunclassified